Sapient Multi-Omics Biomarker Discovery Services

Using state-of-the-art, high-throughput mass spectrometry technologies, Sapient’s proteomics,  metabolomics, and lipidomics approaches enable biopharma sponsors to go beyond the genome with multi-omics biomarker discovery to accelerate precision drug development.

Our large-scale, multi-omics profiling focuses on non-genetic biomarkers – capturing thousands of metabolites, lipids, and proteins per biosample, across thousands of samples at a time – to give you an unprecedented view into the dynamic factors that modulate health, disease, and drug response across individuals.

Using these approaches, we have built an expansive in-house database – our DynamiQ^™ Insights Engine – with multi-omics measures matched with real-world data from >56,000 human biosamples. We can leverage this deeply phenotyped database for longitudinal analysis to uncover dynamic drivers of disease and drug response, confirm biomarker findings in independent human samples, and identify clinical signatures to stratify patients and predict response.

Through our integrated multi-omics biomarker discovery services, including data generation and analysis and biomarker validation and translation, we generate greater biological insight from every sample and enable you to better align disease, patients, and therapies.